<DOC>
	<DOC>NCT01801137</DOC>
	<brief_summary>A study to determine the efficacy of Everolimus(AfinitorÂ®) as third line therapy in patients with transitional cell carcinoma of the urothelium which failed or progressed after two lines of chemotherapy</brief_summary>
	<brief_title>The Efficacy of RAD 001 as Second Line Therapy in Patients With Transitional Cell Carcinoma TCC of the Urothelium</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma, Transitional Cell</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Provision of written informed consent Male or female aged more than 18 years Histologically proven transitional cell carcinoma of the urothelium Metastatic or locally advanced disease not amenable to curative surgery and/or radiotherapy Recurrence or progression after at least one chemotherapy regimen and for unresectable/advanced disease No more than 2 lines of previous chemotherapy.. Measurable disease (RECIST criteria) Previously irradiated lesions are not considered measurable ECOG performance status of 0, 1 or 2 No prior treatment with anti cancer agents, including radiotherapy, in the last 4 weeks. No currently active CNS involvement No pregnancy. Women of child bearing potential must have a negative pregnancy test. No uncontrolled diabetes No symptomatic coronary artery disease, myocardial infarction within the last six months, congestive cardiac failure greater than New York Heart Association (NYHA) class II, uncontrolled or symptomatic cardiac arrhythmia</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>